EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction

BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Kumarakulasinghe, Nesaretnam Barr, Syn, Nicholas, Soon, Yu Yang, Asmat, Atasha, Zheng, Huili, Loy, En Yun, Pang, Brendan, Soo, Ross Andrew
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356756/
https://ncbi.nlm.nih.gov/pubmed/27907909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13458
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы